NCT05009836View on ClinicalTrials.gov

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

September 6, 2021

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Savolitinib

Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

DRUG

Placebo

Subjects will receive placebo orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse

Trial Locations (1)

Unknown

Guangdong General Hospital, Guangzhou

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY